Top Suppliers:I want be here
Related CAS#:
856676-23-8 67-48-1
352438-97-2 4499-40-5
61037-86-3 17773-10-3
28319-77-9 2016-36-6
1334-17-4 285979-70-6

856676-23-8

856676-23-8 structure
856676-23-8 structure
  • Name: Choline Fenofibrate
  • Chemical Name: 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate,2-hydroxyethyl(trimethyl)azanium
  • CAS Number: 856676-23-8
  • Molecular Formula: C22H28ClNO5
  • Molecular Weight: 421.91400
  • Catalog: Signaling Pathways Metabolic Enzyme/Protease Cytochrome P450
  • Create Date: 2018-07-01 16:49:12
  • Modify Date: 2024-01-08 09:50:58
  • Choline Fenofibrate (ABT-335) is the choline salt of fenofibric acid under clinical development as a combination therapy with rosuvastatin for the management of dyslipidemia. IC50 value:Target:Several clinical trials have been developed with Choline Fenofibrate on Reverse Cholesterol Transport, Macular Edema and Hypertriglyceridemia.
Name 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate,2-hydroxyethyl(trimethyl)azanium
Synonyms Choline fenofibrate
UNII-4BMH7IZT98
fenofibric acid choline salt
ABT-335
Fenofibrate de choline
Description Choline Fenofibrate (ABT-335) is the choline salt of fenofibric acid under clinical development as a combination therapy with rosuvastatin for the management of dyslipidemia. IC50 value:Target:Several clinical trials have been developed with Choline Fenofibrate on Reverse Cholesterol Transport, Macular Edema and Hypertriglyceridemia.
Related Catalog
References

[1]. Jones PH, Bays HE, Davidson MH et al. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme. Clin Drug Investig. 2008;28(10):625-34.

[2]. Mohiuddin SM, Pepine CJ, Kelly MT et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J. 2009 Jan;157(1):195-203.

[3]. Zhu T, Awni WM, Hosmane B et al. ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans. J Clin Pharmacol. 2009 Jan;49(1):63-71.

[4]. Goldberg AC, Bays HE, Ballantyne CM et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol. 2009 Feb 15;103(4):515-22.

[5]. Campbell J, Mohiuddin SM. The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes. Drugs Today (Barc). 2010 Oct;46(10):757-64.
Boiling Point 486.5ºC at 760 mmHg
Molecular Formula C22H28ClNO5
Molecular Weight 421.91400
Flash Point 248ºC
Exact Mass 421.16600
PSA 86.66000
LogP 2.16320
Storage condition 2-8℃
600-00-0 structure

600-00-0
42019-78-3 structure

42019-78-3
123-41-1 structure

123-41-1

~70%

856676-23-8 structure

856676-23-8
Literature: US2008/275270 A1, ; Page/Page column 3 ;
42017-89-0 structure

42017-89-0
67-48-1 structure

67-48-1

~75%

856676-23-8 structure

856676-23-8
Literature: WO2010/86700 A2, ; Page/Page column 7 ;
51368-55-9 structure

51368-55-9
42019-78-3 structure

42019-78-3
123-41-1 structure

123-41-1

~68%

856676-23-8 structure

856676-23-8
Literature: US2008/275270 A1, ; Page/Page column 3 ;

Chemsrc provides CAS#:856676-23-8 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 856676-23-8 | Chemsrc address: https://www.chemsrc.com/en/baike/599036.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved